ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.497,94
-0,09%
S&P 500
5.277,51
0,80%
Dow Jones
38.686,32
1,51%
Euro vs US Dollar
1,08565
0,00%
Bitcoin
67.699,36
-0,04%
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Belite Bio Inc (BLTE)

  7. Belite Bio Inc (BLTE) News

BLTE

Belite Bio (BLTE)

Belite Bio Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:BLTE
DatumZeitQuelleÜberschriftSymbolFirma
30/05/202422h45Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BLTEBelite Bio Inc
17/05/202417h36Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BLTEBelite Bio Inc
16/05/202420h23Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BLTEBelite Bio Inc
14/05/202414h00GlobeNewswire Inc.Belite Bio to Participate in the Benchmark’s 4th Annual Healthcare House Call Investor ConferenceNASDAQ:BLTEBelite Bio Inc
14/05/202403h57Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BLTEBelite Bio Inc
14/05/202403h50GlobeNewswire Inc.Belite Bio Reports First-Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:BLTEBelite Bio Inc
13/05/202414h00GlobeNewswire Inc.Belite Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor ConferenceNASDAQ:BLTEBelite Bio Inc
08/05/202414h00GlobeNewswire Inc.Belite Bio to Host Webcast on May 14, 2024, to Discuss First Quarter 2024 Financial ResultsNASDAQ:BLTEBelite Bio Inc
06/05/202414h15GlobeNewswire Inc.Belite Bio to Participate in Key Opinion Leader Webinar to Discuss Unmet Needs In Stargardt Disease (STGD1) and Geographic Atrophy (GA) and Perspectives On TinlarebantNASDAQ:BLTEBelite Bio Inc
06/05/202414h00GlobeNewswire Inc.Belite Bio Presents Additional Analysis from Phase 2 Study of Tinlarebant in Stargardt Disease at the ARVO Annual MeetingNASDAQ:BLTEBelite Bio Inc
01/05/202422h15GlobeNewswire Inc.Belite Bio Announces Presentation at the Association for Research in Vision and Ophthalmology 2024 Annual MeetingNASDAQ:BLTEBelite Bio Inc
26/04/202401h15GlobeNewswire Inc.Belite Bio Announces $25 Million Registered Direct OfferingNASDAQ:BLTEBelite Bio Inc
22/03/202413h00GlobeNewswire Inc.Belite Bio Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in JapanNASDAQ:BLTEBelite Bio Inc
12/03/202403h28GlobeNewswire Inc.Belite Bio Announces Availability of Annual Report on Form 20-F Through Company WebsiteNASDAQ:BLTEBelite Bio Inc
12/03/202402h27GlobeNewswire Inc.Belite Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateNASDAQ:BLTEBelite Bio Inc
06/03/202414h00GlobeNewswire Inc.Belite Bio to Host Webcast on March 12, 2024, to Discuss Fourth Quarter and Full Year 2024 Financial ResultsNASDAQ:BLTEBelite Bio Inc
04/03/202414h00GlobeNewswire Inc.Belite Bio to Participate in the Leerink Partners Global Biopharma ConferenceNASDAQ:BLTEBelite Bio Inc
13/02/202403h08Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:BLTEBelite Bio Inc
13/02/202402h40Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:BLTEBelite Bio Inc
07/02/202414h00GlobeNewswire Inc.Belite Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceNASDAQ:BLTEBelite Bio Inc
28/12/202322h16Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BLTEBelite Bio Inc
28/12/202322h15Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BLTEBelite Bio Inc
30/11/202314h00GlobeNewswire Inc.Belite Bio to Participate in the Benchmark Company’s Upcoming Discovery One-on-One Investor ConferenceNASDAQ:BLTEBelite Bio Inc
28/11/202323h16Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BLTEBelite Bio Inc
20/11/202314h00GlobeNewswire Inc.Belite Bio to Participate in the BTIG Ophthalmology DayNASDAQ:BLTEBelite Bio Inc
16/11/202322h41Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BLTEBelite Bio Inc
16/11/202322h36Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BLTEBelite Bio Inc
14/11/202302h15GlobeNewswire Inc.Belite Bio Reports Third Quarter 2023 Operational Highlights and Financial ResultsNASDAQ:BLTEBelite Bio Inc
10/11/202314h35GlobeNewswire Inc.Deutsche Bank ADR Investor Conference: Presentations Now Available for Online ViewingNASDAQ:BLTEBelite Bio Inc
07/11/202314h00GlobeNewswire Inc.Belite Bio to Host Webcast on November 14, 2023, to Discuss Third Quarter 2023 Financial ResultsNASDAQ:BLTEBelite Bio Inc
 Showing the most relevant articles for your search:NASDAQ:BLTE

Kürzlich von Ihnen besucht

DBI
SDXP
SDAX
DBI
TDXP
Tec DAX
NASDAQ
NVDA
NVIDIA
COIN
BTCUSD
Bitcoin
NASDAQ
TSLA
Tesla
FX
EURJPY
Euro vs Yen
USOTC
RHHBY
Roche (QX)
TG
D7G
Nel ASA
NYSE
MRK
Merck
TG
CBK
Commerzbank
AMEX
SPY
SPDR S&P 500
DBI
DAX
DAX
FX
EURUSD
Euro vs US Dollar
COIN
ETHUSD
Ethereum
NYSE
MCD
McDonalds
NYSE
DIS
Walt Disney
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten